ACD/Labs Announces Katalyst D2D® Software Release with Expanded Capabilities for Accelerated Pharmaceutical Development
Major update to Katalyst D2D will provide support for process scale-up and material characterization in pharmaceutical development Toronto, CANADA (October 23, 2025)—ACD/Labs, an informatics company that develops and commercializes software in support of digitalized R&D, today announced a new release of Katalyst D2D®, the industry-leading software for workflow digitalization and data management in chemical and...
合成分子プロセス開発における自律型ラボの実現
武田薬品工業株式会社様では、研究開発におけるデジタル化と自動化に、多大な時間と労力を費やしてきました。合成分子プロセス開発（SMPD）においては、プロセス最適化を加速する為に、ハイスループット実験（HTE）、並びに自動化技術の構築を推進されています。今回のご講演では、チームでのご経験や知見を基に以下の内容についてお話しいただく予定です。 人の介入を最小限に抑え、データフローと実験実行を可能にする統合システムを用いて、実験時間を数週間から数日 (または数分) に短縮した事例 シームレスなフィードバックループのために分析データ処理を自動化することの重要性 一貫した繰り返し可能な実験から、高品質で再現性のある AI 対応の FAIR データ生成 自動運転ラボに適した標準化されたワークフロー設計 武田薬品工業様のビジョンと24時間365日稼働の自律型ラボに向けた進捗状況
ACD/Labs and Covestro Announce Collaboration Delivering AI-Supported Solvent Selection at PhysChem Forum 2025
The organizations have combined their expertise in chemical synthesis, physicochemical property prediction, and software development to deliver a tool that will transform solvent selection in chemical research through artificial intelligence (AI). Basel, SWITZERLAND (October 13, 2025)—ACD/Labs, an informatics company that develops and commercializes software in support of R&D, and Covestro, a global leader in high-performance...
Redefining Pharmaceutical R&D Through AI and the Digitalized Physical DMTA Cycle
A new two-part white paper series from ACD/Labs examines how AI-enabled design-make-test-analyze (DMTA) cycles can overcome fragmented workflows in drug discovery and development. The series discusses how pharma/biotech organizations can leverage automation and informatics technologies to digitalize workflows empowering faster, robust, and more cost-effective innovation. Toronto, CANADA (September 25, 2025)—ACD/Labs, an informatics company that develops...
Faster, More Confident Structure Verification in Small Molecule R&D
Explore how ASV transforms structure verification into a scalable, consistent and reliable process. This article was originally published on Technology Networks Structure verification in R&D Chemical structure verification is a tedious but critical task in the drug discovery and development pipeline. Despite the advances in automation, AI and high-throughput screening that have revolutionized many other...
DMTA Innovation at Takeda—Digitalized, AI-Augmented, Autonomous
Optimization of chemical process development means exploring complex parameter spaces. Traditional manual approaches are time-consuming, tedious and low throughput. Discover the next generation of AI-driven, digitalized design, make, test, analyze (DMTA) cycles in pharmaceutical R&D with ACD/Labs and Atinary SDLabs™ platform.